Univest Securities, LLC Announces Closing of $4 Million Registered Direct Offering for its Client Haoxi Health Technology Ltd (NASDAQ: HAO)
Univest Securities, LLC said it helped close a registered direct offering for Haoxi Health Technology Ltd (NASDAQ: HAO). Haoxi raised about $4 million by selling 10,000,000 Class A ordinary shares, or pre-funded warrants, at $0.40 per share. Univest acted as sole placement agent.
How this was made
The 30-second read
Why it matters
The disclosed final terms (aggregate $4 million gross proceeds, 10,000,000 Class A shares or pre-funded warrants, $0.40 offering price, $0.33 warrant exercise price) indicate dilution and potential near-term selling pressure, with limited additional fundamentals provided.
Market read
Traders can reassess HAO’s dilution, financing overhang, and near-term valuation risk based on the finalized offering size and pricing.
What to watch
The article does not state use of proceeds, cash balance, or whether the offering price reflects a discount to recent trading, which are key for estimating true dilution impact.
Background
Univest Securities announced the closing of a registered direct offering for Haoxi Health Technology Ltd, referencing an effective shelf registration statement filed in 2025.
Ticker impact
Haoxi Health Technology closed a $4 million registered direct offering, selling 10,000,000 Class A shares (or pre-funded warrants) at $0.40.
Near-term downside bias versus pre-offering levels, with volatility around any warrant exercise mechanics and subsequent financing overhang.
The article discloses the final closing, share count, and offering price, which directly informs dilution and potential selling pressure; no offsetting use-of-proceeds or guidance is provided.
Market effects
Adds another small-cap China healthcare marketing name to the tape with financing overhang risk, but no broader sector policy or demand signal is provided.
Limited regional read-through; the news is issuer-specific with no macro/regulatory catalyst.
Primarily affects HAO and its microcap peer group; no cross-border deal or regulatory action is described.
Counterpoint
If proceeds materially extend runway or fund growth initiatives, the offering could reduce near-term financing risk and stabilize the stock after initial dilution fears.
Key entities
- issuerHaoxi Health Technology Ltd
NASDAQ-listed online marketing solution provider for healthcare advertisers; subject of the registered direct offering closing.
- placement_agentUnivest Securities, LLC
Sole placement agent for the offering.
- regulatorSEC
Referenced for shelf registration effectiveness and prospectus filings.
